(Total Views: 63)
Posted On: 06/24/2025 4:12:24 PM
Post# of 372
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar
CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician of its Brain Tumor Center. Dr. Dunbar discussed the patient journey and current treatment options for Glioblastoma Multiforme (GBM), highlighting CNS’s lead product candidate, TPI 287, and its therapeutic potential for GBM and future metastatic tumor indications.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician of its Brain Tumor Center. Dr. Dunbar discussed the patient journey and current treatment options for Glioblastoma Multiforme (GBM), highlighting CNS’s lead product candidate, TPI 287, and its therapeutic potential for GBM and future metastatic tumor indications.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
